These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

308 related articles for article (PubMed ID: 9674848)

  • 1. CD6+ T cell-depleted allogeneic bone marrow transplantation for non-Hodgkin's lymphoma.
    Soiffer RJ; Freedman AS; Neuberg D; Fisher DC; Alyea EP; Gribben J; Schlossman RL; Bartlett-Pandite L; Kuhlman C; Murray C; Freeman A; Mauch P; Anderson KC; Nadler LM; Ritz J
    Bone Marrow Transplant; 1998 Jun; 21(12):1177-81. PubMed ID: 9674848
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CD6+ T cell depleted allogeneic bone marrow transplantation from genotypically HLA nonidentical related donors.
    Soiffer RJ; Mauch P; Fairclough D; Alyea E; Anderson K; Fisher D; Freedman A; Bartlett-Pandite L; Robertson M; Schlossman R; Gollob J; Marcus K; Murray C; Kuhlman C; Freeman A; Nadler L; Ritz J
    Biol Blood Marrow Transplant; 1997 Apr; 3(1):11-7. PubMed ID: 9209736
    [TBL] [Abstract][Full Text] [Related]  

  • 3. T cell-depleted allogeneic bone marrow transplantation for high-risk non-Hodgkin's lymphoma: clinical and molecular follow-up.
    Juckett M; Rowlings P; Hessner M; Keever-Taylor C; Burns W; Camitta B; Casper J; Drobyski WR; Hanson G; Horowitz M; Lawton C; Margolis J; Peitryga D; Vesole D
    Bone Marrow Transplant; 1998 May; 21(9):893-9. PubMed ID: 9613781
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Allogeneic bone marrow transplantation for relapsed and refractory Hodgkin's disease and non-Hodgkin's lymphoma.
    Dann EJ; Daugherty CK; Larson RA
    Bone Marrow Transplant; 1997 Sep; 20(5):369-74. PubMed ID: 9339751
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Selective T cell depletion of donor allogeneic marrow with anti-CD6 monoclonal antibody: rationale and results.
    Soiffer RJ; Ritz J
    Bone Marrow Transplant; 1993; 12 Suppl 3():S7-10. PubMed ID: 8124262
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A new marrow T cell depletion method using anti-CD6 monoclonal antibody-conjugated magnetic beads and its clinical application for prevention of acute graft-vs.-host disease in allogeneic bone marrow transplantation: results of a phase I-II trial.
    Sao H; Kitaori K; Kasai M; Shimokawa T; Kato C; Yamanishi H; Ueda R; Morishima Y
    Int J Hematol; 1999 Jan; 69(1):27-35. PubMed ID: 10641440
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Donor T-lymphocyte infusion for unrelated allogeneic bone marrow transplantation with CD3+ T-cell-depleted graft.
    Lee CK; deMagalhaes-Silverman M; Hohl RJ; Hayashi M; Buatti J; Wen BC; Schlueter A; Strauss RG; Gingrich RD
    Bone Marrow Transplant; 2003 Jan; 31(2):121-8. PubMed ID: 12621494
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Allogeneic bone marrow transplantation for poor-prognosis non-Hodgkin's lymphoma.
    Shepherd JD; Barnett MJ; Connors JM; Spinelli JJ; Sutherland HJ; Kingemann HG; Nantel SH; Reece DE; Currie CJ; Phillips GL
    Bone Marrow Transplant; 1993 Dec; 12(6):591-6. PubMed ID: 8136743
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term follow-up of allogeneic bone marrow transplantation in patients with poor prognosis non-Hodgkin's lymphoma.
    Bernard M; Dauriac C; Drénou B; Leberre C; Branger B; Fauchet R; Le Prisé PY; Lamy T
    Bone Marrow Transplant; 1999 Feb; 23(4):329-33. PubMed ID: 10100576
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bone marrow transplantation after failure of autologous transplant for non-Hodgkin's lymphoma.
    de Lima M; van Besien KW; Giralt SA; Khouri IF; Mehra R; Andersson BS; Przepiorka D; Gajewski JL; Korbling M; Champlin RE
    Bone Marrow Transplant; 1997 Jan; 19(2):121-7. PubMed ID: 9116608
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Syngeneic hematopoietic stem-cell transplantation for non-Hodgkin's lymphoma: a comparison with allogeneic and autologous transplantation--The Lymphoma Working Committee of the International Bone Marrow Transplant Registry and the European Group for Blood and Marrow Transplantation.
    Bierman PJ; Sweetenham JW; Loberiza FR; Taghipour G; Lazarus HM; Rizzo JD; Schmitz N; van Besien K; Vose JM; Horowitz M; Goldstone A;
    J Clin Oncol; 2003 Oct; 21(20):3744-53. PubMed ID: 12963703
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of patients with myelodysplastic syndromes with allogeneic bone marrow transplantation from genotypically HLA-identical sibling and alternative donors.
    Demuynck H; Verhoef GE; Zachee P; Emonds MP; van der Schueren E; van den Berghe H; Vandenberghe P; Casteels-Van Daele M; Boogaerts MA
    Bone Marrow Transplant; 1996 May; 17(5):745-51. PubMed ID: 8733692
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Allogeneic peripheral blood stem cell transplantation using a fludarabine-based low intensity conditioning regimen for malignant lymphoma.
    Nagler A; Slavin S; Varadi G; Naparstek E; Samuel S; Or R
    Bone Marrow Transplant; 2000 May; 25(10):1021-8. PubMed ID: 10828860
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CD6-depleted allogeneic bone marrow transplantation for acute leukemia in first complete remission.
    Soiffer RJ; Fairclough D; Robertson M; Alyea E; Anderson K; Freedman A; Bartlett-Pandite L; Fisher D; Schlossman RL; Stone R; Murray C; Freeman A; Marcus K; Mauch P; Nadler L; Ritz J
    Blood; 1997 Apr; 89(8):3039-47. PubMed ID: 9108425
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tolerance in DLA-haploidentical canine littermates following CD6-depleted marrow transplantation and donor lymphocyte transfusion.
    Zorn J; Herber M; Schwamberger S; Panzer W; Adler H; Kolb HJ
    Exp Hematol; 2009 Aug; 37(8):998-1006. PubMed ID: 19446000
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Allogeneic or autologous bone marrow transplantation (BMT) for non-Hodgkin's lymphoma (NHL): results of a provincial strategy. Ontario BMT Network, Canada.
    Schimmer AD; Jamal S; Messner H; Keating A; Meharchand J; Huebsch L; Walker I; Benger A; Gluck S; Smith A
    Bone Marrow Transplant; 2000 Oct; 26(8):859-64. PubMed ID: 11081385
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An EBMT registry matched study of allogeneic stem cell transplants for lymphoma: allogeneic transplantation is associated with a lower relapse rate but a higher procedure-related mortality rate than autologous transplantation.
    Peniket AJ; Ruiz de Elvira MC; Taghipour G; Cordonnier C; Gluckman E; de Witte T; Santini G; Blaise D; Greinix H; Ferrant A; Cornelissen J; Schmitz N; Goldstone AH;
    Bone Marrow Transplant; 2003 Apr; 31(8):667-78. PubMed ID: 12692607
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Busulfan and cyclophosphamide as a preparative regimen for allogeneic blood and marrow transplantation in patients with non-Hodgkin's lymphoma.
    Kiss TL; Panzarella T; Messner HA; Meharchand J; Reddy V; Schimmer AD; Lipton JH
    Bone Marrow Transplant; 2003 Jan; 31(2):73-8. PubMed ID: 12621486
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prevention of graft-versus-host disease in high risk patients by depletion of CD4+ and reduction of CD8+ lymphocytes in the marrow graft.
    Herrera C; Torres A; García-Castellano JM; Roman J; Martin C; Serrano J; Falcon M; Alvarez MA; Gomez P; Martinez F
    Bone Marrow Transplant; 1999 Mar; 23(5):443-50. PubMed ID: 10100557
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of allogeneic T cell-depleted peripheral blood stem cell and bone marrow transplantation: effect of stem cell source on short- and long-term outcome.
    Barge RM; Brouwer RE; Beersma MF; Starrenburg CW; Zwinderman AH; Hale G; Waldmann H; den Ottolander GJ; Falkenburg JH; Willemze R; Fibbe WE
    Bone Marrow Transplant; 2001 May; 27(10):1053-8. PubMed ID: 11438820
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.